These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2679219)

  • 21. [Hyposensitization: indications and expectations].
    Urbanek R
    Padiatr Padol; 1990; 25(6):397-404. PubMed ID: 2080061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The best allergen immunotherapy choice for mite allergic patients.
    Ciprandi G; Incorvaia C; Masieri S; Buttafava S; Frati F
    Expert Rev Clin Immunol; 2016 Jun; 12(6):603-4. PubMed ID: 26950287
    [No Abstract]   [Full Text] [Related]  

  • 23. Shooting for a faster approach to the immunotherapy target: will cluster become conventional?
    Cox LS
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062
    [No Abstract]   [Full Text] [Related]  

  • 24. Dendritic cells in allergen-specific immunotherapy.
    Novak N
    Drugs Today (Barc); 2008 Dec; 44 Suppl B():91-2. PubMed ID: 19221629
    [No Abstract]   [Full Text] [Related]  

  • 25. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
    Malling HJ
    Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral routes for immunotherapy: clinical efficacy and kinetics of the allergen.
    Canonica GW; Passalacqua G; Mariani G; Motta C; Bartolomei M; Mistrello G; Falagiani P; Bagnasco M
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1997; (91):56-64; discussion 64-7. PubMed ID: 9383892
    [No Abstract]   [Full Text] [Related]  

  • 27. [The progress on allergen-specific immunotherapy for bronchial asthma].
    Liu HY; Xie LY; Zhou LF
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jun; 36(6):450-4. PubMed ID: 24103210
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hyposensitization].
    Przybilla B; Ring J
    Internist (Berl); 1991 Oct; 32(10):606-11. PubMed ID: 1761393
    [No Abstract]   [Full Text] [Related]  

  • 29. [Desensitization with allergens: early, specific, effective therapy of immune system almost without side effects. Interview by Dr. Barbara Scholtissek].
    Fiebig H; Kahlert H
    Wien Med Wochenschr; 1999; 149(14-15):447, 449-50. PubMed ID: 10584292
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 31. Advances in patent applications related to allergen immunotherapy.
    Silva ES; Pinheiro CS; Quintella CM; Ferreira F; C Pacheco LG; Alcântara-Neves NM
    Expert Opin Ther Pat; 2016 Jun; 26(6):657-68. PubMed ID: 27011299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy.
    Larenas-Linnemann DE
    Allergy Asthma Proc; 2008; 29(2):130-9. PubMed ID: 18430309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Desensitization to antibiotics].
    Moreno Gardea HL; Trevizo de Moreno L
    Rev Alerg Mex; 1997; 44(1):8-12. PubMed ID: 9221103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The history of sublingual immunotherapy.
    Pajno GB; Barberi S
    Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):1-3. PubMed ID: 19944001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allergen immunotherapy. Review of efficacy and current practice.
    Ohman JL
    Med Clin North Am; 1992 Jul; 76(4):977-91. PubMed ID: 1614242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future of allergen-specific immunotherapy: better understanding of the mechanisms, novel treatments, and long-term cure.
    Akdis CA
    Immunol Allergy Clin North Am; 2006 May; 26(2):xiii-xxii. PubMed ID: 16701138
    [No Abstract]   [Full Text] [Related]  

  • 37. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
    Wilcock LK; Francis JN; Durham SR
    Immunol Allergy Clin North Am; 2006 May; 26(2):333-47, viii-ix. PubMed ID: 16701148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyposensitization in general practice. A strategic concept].
    Jorde W
    HNO; 1995 Dec; 43(12):741-4. PubMed ID: 8582837
    [No Abstract]   [Full Text] [Related]  

  • 39. Specific immunotherapy by different allergen applications: subcutaneous, sublingual, oral or rectal administration and lymph node injection.
    Kleine-Tebbe J
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():87-95; discussion 95. PubMed ID: 20799448
    [No Abstract]   [Full Text] [Related]  

  • 40. Advantages and disadvantages of accelerated immunotherapy schedules.
    Cox L
    J Allergy Clin Immunol; 2008 Aug; 122(2):432-4. PubMed ID: 18619664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.